Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02
- 28 March 2009
- journal article
- research article
- Published by Springer Science and Business Media LLC in Supportive Care in Cancer
- Vol. 17 (12), 1483-1491
- https://doi.org/10.1007/s00520-009-0613-7
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Chemotherapy‐induced neuropathyJournal of the Peripheral Nervous System, 2008
- Integrating Patient-Reported Outcomes Into Cancer Symptom Management Clinical Trials Supported by the National Cancer Institute–Sponsored Clinical Trials NetworksJournal of Clinical Oncology, 2007
- Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group studyInternational Journal of Gynecologic Cancer, 2007
- Assessing health-related quality of life in palliative care: Comparing patient and physician assessmentsEuropean Journal of Cancer, 2006
- The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20European Journal of Cancer, 2005
- How Accurate Is Clinician Reporting of Chemotherapy Adverse Effects? A Comparison With Patient-Reported Symptoms From the Quality-of-Life Questionnaire C30Journal of Clinical Oncology, 2004
- Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapyInternational Journal of Gynecologic Cancer, 2003
- Regular review: Peripheral neuropathyBMJ, 2002
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI Journal of the National Cancer Institute, 1993
- Weighted kappa: Nominal scale agreement provision for scaled disagreement or partial credit.Psychological Bulletin, 1968